Vysioneer secures FDA clearance for brain tumor contouring software

By AuntMinnie.com staff writers

April 5, 2021 -- The U.S. Food and Drug Administration (FDA) has cleared artificial intelligence (AI) firm Vysioneer's brain tumor autocontouring software, called VBrain.

VBrain maps three types of brain tumors -- metastasis, meningioma, and acoustic neuroma -- allowing patients to begin radiation therapy more quickly than when contouring must be performed manually, the company said.

VBrain applies autocontouring to the three most common types of brain tumors
VBrain applies autocontouring to the three most common types of brain tumors: brain metastasis, meningioma, and acoustic neuroma. Image courtesy of Vysioneer.

In an 18-month clinical trial conducted at the National Taiwan University Hospital in Taipei, researchers found that VBrain had a 12.2% higher sensitivity for detecting lesions compared with manual contouring, and it decreased treatment planning time by 30.8%, Vysioneer said.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: